Nature Reviews Urology - Table of Contents alert Volume 14 Issue 1

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
January 2017 Volume 14 Number 1
2015 2-year Impact Factor 5.957 *	In this issue Editorial Comment Research Highlights News and Views Reviews Perspectives
Subscribe   Facebook   RSS   Recommend to library   Twitter
EDITORIAL		Top
Illustrating the wealth of urology Published online: 30 December 2016 p1 | doi:10.1038/nrurol.2016.250 Full Text | PDF
Comment: Paediatric renal tumours: perspectives from the SIOP-RTSG Published online: 06 December 2016 p3 | doi:10.1038/nrurol.2016.247 Abstract | Full Text | PDF
RESEARCH HIGHLIGHTS Top Testicular cancer: Origin and evolution of TGCTs Published online: 06 December 2016 p5 | doi:10.1038/nrurol.2016.255 PDF Erectile dysfunction: Too much ROCK — erection block Published online: 08 November 2016 p6 | doi:10.1038/nrurol.2016.231 PDF See also: Review by Sopko et al. Understanding and targeting the Rho kinase pathway in erectile dysfunction Erectile dysfunction (ED) is a common disorder that affects a quarter of US men, and has many causes, including endothelial impairment, low testosterone levels, prior surgical manipulation, and/or psychogenic components. Penile erection is a complex process requiring neurally mediated relaxation of arteriolar smooth muscle and engorgement of cavernosal tissues, mediated by nitric oxide (NO). Current medical therapies for ED largely seek to maximize endogenous NO signalling. Certain aetiologies, including diabetes, are difficult to treat with current modalities, emphasizing the need for new molecular targets. Research has demonstrated the importance of RhoA-Rho-associated protein kinase (ROCK) signalling in maintaining a flaccid penile state, and inhibition of RhoA-ROCK signalling potentiates smooth-muscle relaxation in an NO-independent manner. The mechanisms and effects of RhoA-ROCK signalling and inhibition suggest that the RhoA-ROCK pathway could prove to be a new therapeutic target for the treatment of ED. Review by Sopko et al. Infection: Transcriptome remodelling explains UTI recurrence Published online: 15 November 2016 p6 | doi:10.1038/nrurol.2016.242 PDF Prostate cancer: On target — theranostic imaging for aggressive disease Published online: 08 November 2016 p7 | doi:10.1038/nrurol.2016.230 PDF Prostate cancer: Role for EGFR & HER2 in bone metastasis Published online: 15 November 2016 p7 | doi:10.1038/nrurol.2016.241 PDF Kidney cancer: Methylation panel predicts RCC outcome Published online: 02 November 2016 p8 | doi:10.1038/nrurol.2016.226 PDF Prostate cancer: A glitch in the extracellular matrix Published online: 15 November 2016 p8 | doi:10.1038/nrurol.2016.238 PDF In the news: From EMUC16 Published online: 06 December 2016 p8 | doi:10.1038/nrurol.2016.258 PDF Prostate cancer: BRN2 is a neuroendocrine driver Published online: 15 November 2016 p10 | doi:10.1038/nrurol.2016.237 PDF Development: AR signalling and sexual development Published online: 29 November 2016 p10 | doi:10.1038/nrurol.2016.245 PDF Urinary incontinence: Detrusor activity predicts renal damage Published online: 29 November 2016 p10 | doi:10.1038/nrurol.2016.246 PDF IN BRIEF Kidney cancer: High-affinity Fc-γ variants improve IL-2 responses | Bladder cancer: Autologous NK cells active against high-risk cancer | Urinary incontinence: Effects of anterior root stimulation are sustained | Kidney cancer: Somatic mutations predict survival duration PDF Urology JOBS of the week Urologic Oncologist Northwestern University Feinberg School of Medicine, Chicago More Science jobs from
NEWS AND VIEWS		Top
Incontinence: Treating women with refractory urge urinary incontinence Roger Dmochowski Published online: 06 December 2016 p11 | doi:10.1038/nrurol.2016.244 Onabotulinumtoxin A and sacral neuromodulation are options for treating women with refractory urge urinary incontinence. Both of these treatment options provide symptomatic relief and have advantages and drawbacks. Discussion with patients regarding the risks and benefits of each therapy is critical for informed treatment choice. Full Text | PDF
Bladder cancer: Advancing NMIBC treatment beyond current BCG formulations Hideyuki Akaza Published online: 06 December 2016 p12 | doi:10.1038/nrurol.2016.248 Multiple BCG strains are used for intravesical instillation treatment of non-muscle-invasive bladder cancer but no large randomized studies comparing these strains are available. To enable creation of new BCG-related agents that overcome the instabilities of the current formulations, molecular examination of BCG's mechanisms of action is required. Full Text | PDF
REVIEWS		Top
Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations Jeffrey J. Tosoian et al. Published online: 11 October 2016 p15 | doi:10.1038/nrurol.2016.175 A diagnosis of oligometastatic prostate cancer has become increasingly common, as diagnostic techniques have become more effective. However, the optimal management of patients with oligometastatic disease, and even the exact definition of oligometastasis itself, remains unclear. In this Review, Tosoian and colleagues examine the available data and offer their expert opinion on diagnosis, definition and management of the oligometastatic state. Abstract | Full Text | PDF
The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA Katherine Fleshner, Sigrid V. Carlsson & Monique J. Roobol Published online: 20 December 2016 p26 | doi:10.1038/nrurol.2016.251 In 2012, the United States Preventive Services Task Force issued a Grade D recommendation for PSA screening — in essence, a recommendation for cessation of prostate cancer screening in all US men. In this Review, the authors discuss the effect of this statement on prostate cancer incidence and dynamics, as well as changes in attitudes to screening of patients and health-care providers in the USA. Abstract | Full Text | PDF
The role of GATA2 in lethal prostate cancer aggressiveness Veronica Rodriguez-Bravo et al. Published online: 22 November 2016 p38 | doi:10.1038/nrurol.2016.225 The endothelial transcription factor GATA2 has been reported to have a key role in driving prostate cancer aggressiveness. GATA2 overexpression in prostate cancer increases cellular motility and invasiveness, proliferation, tumorigenicity, and resistance to standard therapies. Thus, GATA2 is a highly attractive target for the development of novel treatments against lethal prostate cancer. Abstract | Full Text | PDF
Androgen synthesis in prostate cancer: do all roads lead to Rome? Ryan Stuchbery, Patrick J. McCoy, Christopher M. Hovens & Niall M. Corcoran Published online: 08 November 2016 p49 | doi:10.1038/nrurol.2016.221 Treatment with androgen-deprivation therapy can delay the progression of prostate cancer. However, acquired resistance to such approaches is very common. Here the authors describe the role of androgen synthesis pathways, including the specific relevance of each individual pathway, to the development of castration-resistant prostate cancer. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION Clinical and molecular rationale to retain the cancer descriptor for Gleason score 6 disease Chad A. Reichard & Eric A. Klein Published online: 29 November 2016 p59 | doi:10.1038/nrurol.2016.240 Reichard and Klein present clinical and molecular data that stand against removing the cancer descriptor from Gleason score 3 + 3=6 prostate cancer. They argue that the evidence of a lack of malignancy is inconclusive and that a change in classification might result in poor patient outcomes. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2008. Nature Reviews Urology was previously published as Nature Clinical Practice Urology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.